Triplet therapy shows strongest survival benefit in mHSPC with visceral disease
/0 Comments/in Review/by MaxNewsletter 28/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! More good news this week! I’d like to take this opportunity to ask you something: would you like me to include a link to the full article on ProstateWarriors.com in the newsletter? So far, I haven’t done it because […]
New Combination Therapy Gets Fast Tracked: 177Lu-PSMA-617 (Pluvicto) Plus TRE-515
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNew Phase 3 Trial Approved for Masitinib for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxMetformin and Prostate Cancer: A Review of STAMPEDE Trial from The Lancet
/0 Comments/in Review/by MaxNewsletter 27/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week has been a bit of a whirlwind, I’ve been working on my own research project. But we do have some interesting studies and a promising update!Stay strong and fight on! As usual, we also have a podcast […]
Korean Team Unveils Breakthrough All-in-One Cancer Nanomedicine
/0 Comments/in Preclinical Research/by MaxIn a groundbreaking advancement for cancer treatment, a team from the Korea Research Institute of Standards and Science (KRISS) has developed an innovative nanomaterial that could transform cancer care. This “all-in-one” nanomedicine, known as gold-iron-gold nanodisks (AuFeAuNDs), integrates diagnosis, treatment, and immune activation into a single platform. Still in pre-clinical stages, this discovery shows significant […]
Early Results of Gedatolisib and Darolutamide in mCRPC Treatment
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
Latest Posts
- IND Required for ITC-6146RO for Solid Tumors Overexpressing the B7-H3 Protein September 2, 2025
- Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer August 30, 2025
- Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN) August 29, 2025
- Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer August 29, 2025